CD274 and neoplasm: In conclusion, we have shown that an anti-PD-L1 mAb exerted its antitumor activity through the blocking of PD-L1 in tumor-draining lymph nodes as well as at the tumor site, which would provide a scientific rationale for the efficacy of PD-L1 antibodies in patients with little intratumoral PD-L1 expression.